Myelodysplastic Syndromes (MDS) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with ... - GlobeNewswire (press release)



Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with ... 
GlobeNewswire (press release)
Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia ...

and more » 


25 Lakh In A Day To Help Cancer Patient In Mumbai - NDTV



NDTV
 
25 Lakh In A Day To Help Cancer Patient In Mumbai 
NDTV
13 lakh for his college fees. Rushi wrote he always dreamed of earning his MBA and his parents never once let the worry of finances prevent him from pursuing his dreams. But a diagnosis of myelodysplastic syndromes (MDS) briefly derailed Rushi's plans.

and more » 


Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms - Dove Medical Press



Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms 
Dove Medical Press
Materials and methods: A female patient was diagnosed with MDS/MPN through bone marrow cytology, immunology, cell genetics, molecular biology, and pathology. She received thalidomide and prednisone as initial treatment. Ten months later, the first-line ...

 


Myelodysplastic Syndrome (MDS) Therapeutics Market Overview 2017 to 2022 - E News Access (press release)



Myelodysplastic Syndrome (MDS) Therapeutics Market Overview 2017 to 2022 
E News Access (press release)
Global Myelodysplastic Syndrome (MDS) Therapeutics Market Research Report 2017 to 2022 presents an in-depth assessment of the Myelodysplastic Syndrome (MDS) Therapeutics including enabling technologies, key trends, market drivers, challenges, ...

 


Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes - GlobeNewswire (press release)



Weekly Register
 
Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes 
GlobeNewswire (press release)
... potential treatment of adult patients with transfusion-dependent anemia due to Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are non-del(5q) and who are refractory or resistant to treatment with an erythropoiesis stimulating agent ...
Geron up 13% premarket on US Fast Track for imetelstat for MDS Seeking Alpha
Geron Shares Rise on Fast Track Designation -- Biotech Movers TheStreet.com
Geron Announces Presentations at American Society of Hematology Annual Meeting Nasdaq
StockNewsGazette  -WallStreetPR  -Zacks.com  -Zacks Investment Research 
all 106 news articles » 


Rafael Pharmaceuticals and Atlantic Health System, Initiate a Phase I Clinical Trial for Patients with Locally ... - TAPinto.net



Rafael Pharmaceuticals and Atlantic Health System, Initiate a Phase I Clinical Trial for Patients with Locally ... 
TAPinto.net
... (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS).

and more » 


Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor ... - Markets Insider



Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor ... 
Markets Insider
... with a primary focus on Myelodysplastic Syndromes (MDS), has presented data on a new formulation of rigosertib with enhanced bioavailability, as well as pre-clinical data on metabolism and bioavailability for a first-in-class dual inhibitor of CDK4 ...

 


Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)



Onconova Therapeutics Announces Pricing of Public Offering of Common Stock 
GlobeNewswire (press release)
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's ...
Critical Contrast: Onconova Therapeutics (ONTX) and The Competition The Ledger Gazette
Head-To-Head Contrast: Onconova Therapeutics (ONTX) & Baxalta ... Dispatch Tribunal

all 15 news articles » 


Atlantic Health System Announces Clinical Trial of Drug for Locally ... - TAPinto.net



TAPinto.net
 
Atlantic Health System Announces Clinical Trial of Drug for Locally ... 
TAPinto.net
Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation of a ...

and more » 


Head to Head Review: Onconova Therapeutics (NASDAQ:ONTX) vs. Baxalta (BXLT) - The Ledger Gazette



Head to Head Review: Onconova Therapeutics (NASDAQ:ONTX) vs. Baxalta (BXLT) 
The Ledger Gazette
... rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and ...